Skip to main content
Premium Trial:

Request an Annual Quote

Doheny Named CEO of OpGen, Millipore's Madaus Joins Predicitive Biosciences' Board, and More

NEW YORK (GenomeWeb News) – OpGen has hired Noel Doheny to take over as CEO and as a member of the company’s board of directors. Doheny recently was senior VP of molecular diagnostics at Affymetrix, and he has been in leadership roles at Biostar, Qiagen, and Ciba-Corning.

Genetix Group has appointed Jerry Williamson to the post of president of US operations, a new position. Williamson formerly served as president of Biacore, was president of the genomics company Pyrosequencing, and was in commercial management at Genzyme and at Roche Laboratories.

Mark Ostrowski has joined GenVault as VP of sales and marketing. Ostrowski spent over a decade with Myriad Genetics Laboratories, finishing his tenure there as director of sales operations. He also was involved in commercialization of pathology and oncology diagnostics at the company Dianon, which later was purchased by LabCorp.

RXi Pharmaceuticals CFO Stephen DiPalma and Athena Diagnostics VP of business development Michael Henry have been named to the board of directors at Neuroptix

Predictive Biosciences has appointed Martin Madaus to its board of directors. Madaus is president, CEO, and chairman of Millipore and he formerly was VP of development at Roche Molecular Diagnostics and a GM at Boehringer Mannheim.

Janelle Hoskins has been named director of the Molecular Genomics Facility at the University of North Carolina at Chapel Hill’s Institute for Pharmacogenomics and Individualized Therapy.

Vivian Cheung has been named an investigator by the Howard Hughes Medical Institute. Cheung, who is a pediatric neurologist at the Children’s Hospital of Philadelphia and the University of Pennsylvania School of Medicine, studies the links between gene expression and individual susceptibility to disease and treatment responses.

Elisabeth Allison has joined Helicos BioSciences’ board of directors. Allison is a partner at ANZI Partners, and is chief negotiator for ANZI Partners’ publishing media and software ventures and was an associate professor in economics at Harvard University.

Q Chip has appointed Ken Powell as executive chairman. Powell previously was CEO of Arrow Therapeutics.

The National Institutes of Health has tapped Thomas Kelly and Keith Yamamoto to join its Advisory Committee to the Director.
Kelly is a director of the Sloan-Kettering Institute at the Memorial Sloan-Kettering Cancer Center, and a professor at Weill Graduate School of Biomedical Sciences at Cornell University. Kelly spent 30 years at the Johns Hopkins University School of Medicine, where he was director of the Department of Molecular Biology and Genetics and the director of the Institute for Basic Biomedical Sciences.
Yamamoto is a professor of cellular and molecular pharmacology and executive vice dean of the School of Medicine at the University of California, San Francisco, where he also has been vice chair of the department of biochemistry and biophysics and chair of the department of cellular and molecular pharmacology.

The Structural Genomics Consortium has named Chas Bountra to be chief scientist at its lab at the University of Oxford. Bountra will lead a group of 65 scientists at the SGC lab and will oversee new initiatives such as the new chemical biology effort.

The Kauffman Foundation has tapped Bo Fishback to be VP of entrepreneurship. Fishback formerly worked with BioMed Valley Discoveries and he is a co-founder of the sequencing company Lightspeed Genomics.

ImaGenes has appointed Ivan Baines, Peter Lichter, and Klaus Schmidt-Meschner to its advisory board. Baines is director of services and facilities at the Max Planck Institute for Molecular Cell Biology in Dresden. Lichter is an array technology expert at the German Cancer Research Center in Heidelberg. Schmidt-Menschner formerly was an executive at Bayer AG.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.